Yen Weakens After Intervention Spike as Dollar Stabilizes Amid Global Tensions 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
US Stock Futures Rise as S&P 500 and Nasdaq Hit Record Highs Amid Earnings Optimism and Iran Tensions 
China Manufacturing PMI Beats Forecasts in April Amid Weak Domestic Demand 
Dollar Holds Near Two-Week High as Fed Hawkish Shift Lifts Yields, Yen Near Intervention Zone 
Dollar Gains Slightly as Yen Volatility Continues After Japan Intervention 
Markets Stay Strong Despite Oil Shock Concerns as Earnings Drive Investor Confidence 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
US-Iran Conflict Escalates Amid Oil Blockade and Rising Global Tensions 
Oil Prices Surge Amid U.S.-Iran Tensions and Supply Disruption Fears 
Panama Defends Port Takeover Amid U.S.-China Tensions and Canal Dispute 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Celltrion revealed on Thursday, Sept. 23, that it would be supplying its rapid COVID-19 test kit called DiaTrust to the US government. This happened after the nation’s Department of Defense awarded the contract to them.
The South Korean biopharma stated that starting October 1st, its American division, Celltrion USA, will begin delivering the DiaTrust rapid test kits to 25,000 locations. The sites include nursing homes, coronavirus testing centers, and military facilities.
According to The Korea Herald, based on the agreement signed by Celltrion and the US Defense Logistics Agency, the United States could purchase additional kits if necessary. For the initial supply, the amount of the contract is said to be $626.61 million or 738.2 billion in Korean won.
Details for the initial order, like how many would be delivered was not disclosed. However, the publication stated that Bloomberg mentioned that the deal was for a total of 19 million DiaTrust test kits. With its contract with the DOD, Celltrion became the US’ largest supplier of rapid COVID-19 test kits.
“The fact that we were awarded a procurement contract by the DLA after having passed its strict screen process is a recognition of Celltrion’s technology and supply capability,” Celltrion USA chief executive officer, Bonjoong Kim, said in a press release. “With the COVID-19 pandemic still not showing signs of waning, we plan to focus on executing this contract as diligently as possible and further solidify the external credibility of Celltrion’s diagnostic test kits portfolio.”
It was added that the DiaTrust kits that will be delivered through this deal are point-of-care tests (POCT). This means that the COVID-19 rapid test will only be used in the presence of medical professionals. Apparently, this is for safety and to ensure that the process is done properly for more accurate results.
As per Pulse News, DiaTrust was jointly developed by Celltrion and Humasis, a Korean R&D company. The test kit was authorized by the US Food and Drug Administration (FDA) for emergency use last April.
Finally, Celltrion’s DiaTrust rapid COVID-19 kit is an antigen test that is used in medical settings. It can reveal the results on the spot since it only takes as little as 15 minutes to complete.
